Fig. 1
From: Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
Effect of veliparib on MGMT unmethylated patient derived cell lines. a Dose-response curves of PDCLs treated with veliparib compared to untreated cells. b Combination of veliparib (0, 5 or 10 μM) with temozolomide (TMZ; 150 or 300 μM). Bar graphs represent percentage viability of cells after 8 days of treatment. Error bars represent the standard deviation of three individual experiments. Significance determined by student t-test where ***(p < 0.001)